{"id":"placebo-upa","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo-UPA appears to be a placebo formulation used as a control arm in Phase 3 clinical trials conducted by The University of Hong Kong. Without knowledge of the active comparator drug in these trials, the specific therapeutic mechanism cannot be determined. Placebos are inert substances used to establish efficacy and safety baselines in randomized controlled trials.","oneSentence":"This is a placebo control used in clinical trials and does not have an active pharmaceutical mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:08.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05878119","phase":"PHASE2","title":"Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2023-10-25","conditions":"Healthy","enrollment":124},{"nctId":"NCT06727734","phase":"PHASE3","title":"Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-12","conditions":"Contraception","enrollment":980},{"nctId":"NCT04927975","phase":"PHASE2","title":"Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-06-30","conditions":"Non-Segmental Vitiligo","enrollment":185},{"nctId":"NCT06284642","phase":"PHASE4","title":"Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-03-28","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":424},{"nctId":"NCT04159831","phase":"PHASE2","title":"A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions","status":"COMPLETED","sponsor":"Rein Therapeutics","startDate":"2020-09-26","conditions":"Pleural Effusion","enrollment":44},{"nctId":"NCT03823378","phase":"PHASE2","title":"A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-05-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":97},{"nctId":"NCT01663792","phase":"NA","title":"Dietary Seaweed and Early Breast Cancer: A Randomized Trial","status":"COMPLETED","sponsor":"University of South Carolina","startDate":"2006-10","conditions":"Seaweed Associated Changes in Healthy Subjects","enrollment":15},{"nctId":"NCT03682705","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":242},{"nctId":"NCT01694381","phase":"EARLY_PHASE1","title":"Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor","status":"TERMINATED","sponsor":"TSI, LLC","startDate":"2012-09","conditions":"Acute Ischemic Stroke","enrollment":8},{"nctId":"NCT03027973","phase":"PHASE1","title":"Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2020-01","conditions":"Heavy Menstrual Bleeding","enrollment":""},{"nctId":"NCT02147158","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-01-29","conditions":"Leiomyoma, Uterine Hemorrhage","enrollment":432},{"nctId":"NCT02147197","phase":"PHASE3","title":"A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-03-31","conditions":"Leiomyoma, Uterine Hemorrhage","enrollment":157},{"nctId":"NCT03186586","phase":"PHASE4","title":"Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2017-07-01","conditions":"Heavy Menstrual Bleeding, Abnormal Bleeding","enrollment":32},{"nctId":"NCT01222117","phase":"PHASE2","title":"A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2010-12","conditions":"Acute Peripheral Arterial Occlusion","enrollment":174},{"nctId":"NCT01569113","phase":"PHASE4","title":"Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.","status":"COMPLETED","sponsor":"HRA Pharma","startDate":"2012-03","conditions":"Emergency Contraception","enrollment":76},{"nctId":"NCT01553123","phase":"PHASE3","title":"Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma","status":"WITHDRAWN","sponsor":"Watson Pharmaceuticals","startDate":"2012-04","conditions":"Leiomyomas","enrollment":""},{"nctId":"NCT01391845","phase":"NA","title":"Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern","status":"UNKNOWN","sponsor":"Programa de Asistencia Reproductiva de Rosario","startDate":"2011-07","conditions":"Infertility","enrollment":16},{"nctId":"NCT01134237","phase":"PHASE3","title":"Intrapleural Urokinase for Retained Hemothorax","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-05","conditions":"Retained Hemothorax","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo - UPA","genericName":"Placebo - UPA","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}